Showing 1241-1250 of 1395 results for "".
- FDA Clears Novoxel's Tixel for the Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/Isreal-based Novoxel announced the the FDA clearance of its Tixel device for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction (MGD). The Tixel systems use proprietary Thermo-Mechanical Actio
- BVI Introduces Serenity and Serenity Toric IOLshttps://modernod.com/news/bvi-to-unveil-serenity-and-serenity-toric-premium-monofocal-iols-at-escrs/2482420/BVI has introduced the Serenity and Serenity Toric premium monofocal IOLs, which it plans to launch in Europe at the upcoming ESCRS congress in Barcelona. These non-diffractive, aspheric IOLs represent the second generation of BVI’s Isopure family, launched in 2019
- Ocuvex Therapeutics Acquires Visiox Pharmaceuticalshttps://modernod.com/news/visiox-pharmaceuticals-merges-with-ocuvex-therapeutics/2482402/Early-stage ophthalmic biotech company Ocuvex Therapeutics announced an agreement to acquire Visiox Pharmaceuticals. Terms of the deal were not disclosed. Visiox's lead asset is Omlonti (omidenepag isopropyl ophthalmic solution 0.002%), an EP2 rece
- Bausch + Lomb Publishes Teneo Excimer Laser Clinical Trial Resultshttps://modernod.com/news/bausch-lomb-publishes-teneo-excimer-laser-clinical-trial-results/2482393/Bausch + Lomb announced the publication of clinical trial results for its Teneo Excimer Laser in the August issue of the Journal of Refractive Surgery. These findings supported the FDA approval of the Teneo platform for LASIK in January 2024, specifically for myopia and myopic astig
- Opthea Welcomes International Retina Thought Leaders to Its Medical Advisory Boardhttps://modernod.com/news/opthea-welcomes-international-retina-thought-leaders-to-its-medical-advisory-board/2482361/Opthea announced the formation of its Medical Advisory Board, which will comprise of 10 retina thought leaders from countries around the world, including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medica
- FDA Accepts Eluminex Biosciences' IND Application for Trispecific Fusion Antibody for DMEhttps://modernod.com/news/fda-accepts-eluminex-biosciences-ind-application-for-trispecific-fusion-antibody-for-dme/2482259/Eluminex Biosciences announced the acceptance of its EB-105 IND application to the FDA. EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DM
- Prevent Blindness Opens Nominations for the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Awardhttps://modernod.com/news/prevent-blindness-opens-nominations-for-the-2024-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award/2482043/Prevent Blindness is issuing the call for nominations for the “2024 Jenny Pomeroy Award for Excellence in Vision and Public Health,” and the fifth annual “
- Pixium Vision: Date Scheduled for Decision on Adoption of a Sale Planhttps://modernod.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/Pixium Vision SA announced that following a hearing on Monday, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings. In the event of the opening of judicial l
- IRIS Registry-based Study Evaluates Side-Effect of Semaglutide Weight-Loss Drug on Diabetic Retinopathyhttps://modernod.com/news/iris-registry-based-study-evaluates-side-effect-of-semaglutide-weight-loss-drug-on-diabetic-retinopathy/2481947/According to the American Academy of Ophthalmology (AAO), new review of real-world data offers reassurance for the use of the diabetes drug semaglutide, which is popular for helping people lower their glucose levels and better manage their weight. At issue has been that a potential side effect of
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s